Tech Company Financing Transactions
CG Oncology Funding Round
Foresite Capital, Acorn Bioventures and Ally Bridge Group invested in a $105 million funding round for CG Oncology. The round was recorded on 8/3/2023.
Transaction Overview
Company Name
Announced On
8/3/2023
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Undisclosed
Investors
Proceeds Purpose
CG Oncology plans to use the oversubscribed financing to progress clinical programmes in bladder cancer and obtain approval from the US Food and Drug Administration (FDA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Spectrum Center Dr. 2040
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2010, CG Oncology is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies. CG Oncology is currently investigating the company's first product, CG0070, for the treatment of NMIBC in the BCG-unresponsive patient population.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Kuan
Chief Medical Officer
James Burke
Chief Scientific Officer
Paola Grandi
Chief Technical Officer
Georg Roth
Controller
Amy Steele
VP - Bus. Development
Bing Kung
VP - Operations
John McAdory
VP - Regulatory Affairs
Ursula Fritsch
VP - Regulatory Affairs
Jeffrey Ouano
Browse more venture capital transactions:
Prev: 8/3/2023: Haus venture capital transaction
Next: 8/3/2023: Orbital venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs